Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.
Humans
Colorectal Neoplasms
/ drug therapy
Bevacizumab
/ therapeutic use
Trifluridine
/ therapeutic use
Thymine
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Pyrrolidines
/ therapeutic use
Drug Combinations
Neoplasm Metastasis
Progression-Free Survival
Uracil
/ analogs & derivatives
Drug Resistance, Neoplasm
Bevacizumab
Colorectal cancer
Trifluridine-tipiracil
anti-VEGF antibody
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
received:
30
01
2024
accepted:
29
05
2024
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
2
6
2024
Statut:
epublish
Résumé
Colorectal cancer is the leading cause of cancer death worldwide. The first and second lines of treatment for metastatic colorectal cancer (mCRC) include chemotherapy based on 5-fluorouracil. However, treatment following progression on the first and second line is still unclear. We searched PubMed, Scopus, Cochrane, and Web of Science databases for studies investigating the use of trifluridine-tipiracil with bevacizumab versus trifluridine-tipiracil alone for mCRC. We used RStudio version 4.2.3; and we considered p < 0.05 significant. Seven studies and 1,182 patients were included - 602 (51%) received trifluridine-tipiracil plus bevacizumab. Compared with control, the progression-free survival (PFS) (HR 0.52; 95% CI 0.42-0.63; p < 0.001) and overall survival (OS) (HR 0.61; 95% CI 0.52-0.70; p < 0.001) were significantly higher with bevacizumab. The objective response rate (ORR) (RR 3.14; 95% CI 1.51-6.51; p = 0.002) and disease control rate (DCR) (RR 1.66; 95% CI 1.28-2.16; p = 0.0001) favored the intervention. Regarding adverse events, the intervention had a higher rate of neutropenia (RR 1.38; 95% CI 1.19-1.59; p = 0.00001), whereas the monotherapy group had a higher risk of anemia (RR 0.60; 95% CI 0.44-0.82; p = 0.001). Our results support that the addition of bevacizumab is associated with a significant benefit in PFS, OS, ORR and DCR.
Identifiants
pubmed: 38825703
doi: 10.1186/s12885-024-12447-8
pii: 10.1186/s12885-024-12447-8
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Trifluridine
RMW9V5RW38
Thymine
QR26YLT7LT
Pyrrolidines
0
trifluridine tipiracil drug combination
0
Drug Combinations
0
Uracil
56HH86ZVCT
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
674Informations de copyright
© 2024. The Author(s).
Références
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
pubmed: 36633525
doi: 10.3322/caac.21763
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.
pubmed: 35020204
doi: 10.3322/caac.21708
Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10–32.
pubmed: 36307056
doi: 10.1016/j.annonc.2022.10.003
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, et al. Colon cancer, Version 2.2021, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:329–59.
pubmed: 33724754
doi: 10.6004/jnccn.2021.0012
Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–46.
pubmed: 27108243
doi: 10.1016/S1470-2045(16)00150-9
Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib Plus Cetuximab as a New Standard of Care for previously treated BRAF V600E-Mutant metastatic colorectal Cancer: updated survival results and subgroup analyses from the BEACON Study. J Clin Oncol. 2021;39:273–84.
pubmed: 33503393
pmcid: 8078423
doi: 10.1200/JCO.20.02088
Arnold D, Prager GW, Quintela A, Stein A, Moreno Vera S, Mounedji N, et al. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol. 2018;29:835–56.
pubmed: 29452346
pmcid: 5913602
doi: 10.1093/annonc/mdy038
Mauri G, Gori V, Bonazzina E, Amatu A, Tosi F, Bencardino K, et al. Oxaliplatin retreatment in metastatic colorectal cancer: systematic review and future research opportunities. Cancer Treat Rev. 2020;91:102112.
pubmed: 33091698
doi: 10.1016/j.ctrv.2020.102112
Amatu A, Mauri G, Tosi F, Bencardino K, Bonazzina E, Gori V, et al. Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal Cancer patients: the RETROX-CRC retrospective study. Cancers (Basel). 2022;14:1197.
pubmed: 35267504
doi: 10.3390/cancers14051197
Cremolini C, Rossini D, Dell’Aquila E, Lonardi S, Conca E, Del Re M, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5:343–50.
pubmed: 30476968
doi: 10.1001/jamaoncol.2018.5080
Chan BM, Hochster HS, Lenz H-J. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: a pharmacy perspective. Am J Health Syst Pharm. 2019;76:339–48.
pubmed: 31361848
doi: 10.1093/ajhp/zxy006
Martinez-Perez J, Riesco-Martinez MC, Garcia-Carbonero R. The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. Expert Opin Drug Saf. 2018;17:643–50.
pubmed: 29745737
doi: 10.1080/14740338.2018.1475557
Falcone A, Ohtsu A, Van Cutsem E, Mayer RJ, Buscaglia M, Bendell JC, et al. Integrated safety summary for trifluridine/tipiracil (TAS-102). Anticancer Drugs. 2018;29:89–96.
pubmed: 29176395
doi: 10.1097/CAD.0000000000000554
Lee JJ, Chu E. Adherence, dosing, and managing toxicities with Trifluridine/Tipiracil (TAS-102). Clin Colorectal Cancer. 2017;16:85–92.
pubmed: 28242161
pmcid: 5743195
doi: 10.1016/j.clcc.2017.01.003
Voutsadakis IA. Biomarkers of trifluridine-tipiracil efficacy. J Clin Med. 2021;10:5568.
pubmed: 34884270
pmcid: 8658167
doi: 10.3390/jcm10235568
Otsu S, Hironaka S. Current status of angiogenesis inhibitors as second-line treatment for unresectable colorectal Cancer. Cancers (Basel). 2023;15:4564.
pubmed: 37760533
doi: 10.3390/cancers15184564
Lim SH, Cho HJ, Kim K-M, Lim HY, Kang WK, Lee J, et al. Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer. Oncol Res. 2023;31:855–66.
pubmed: 37744267
pmcid: 10513961
doi: 10.32604/or.2023.030374
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.
pubmed: 23168366
doi: 10.1016/S1470-2045(12)70477-1
Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol. 2017;18:1172–81.
pubmed: 28760399
doi: 10.1016/S1470-2045(17)30425-4
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–19.
pubmed: 25970050
doi: 10.1056/NEJMoa1414325
Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13:993–1001.
pubmed: 22951287
doi: 10.1016/S1470-2045(12)70345-5
Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, et al. Results of a Randomized, Double-Blind, Placebo-Controlled, phase III trial of Trifluridine/Tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal Cancer: the TERRA Study. J Clin Oncol. 2018;36:350–8.
pubmed: 29215955
doi: 10.1200/JCO.2017.74.3245
Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, Benavides M, et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018;90:63–72.
pubmed: 29274618
doi: 10.1016/j.ejca.2017.10.009
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
pubmed: 33782057
pmcid: 8005924
doi: 10.1136/bmj.n71
Cochrane Handbook for Systematic Reviews of Interventions. https://training.cochrane.org/handbook . Accessed 14 Jan 2024.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
pubmed: 19097774
doi: 10.1016/j.ejca.2008.10.026
Common Terminology Criteria for Adverse Events (CTCAE). 2017.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
pubmed: 31462531
doi: 10.1136/bmj.l4898
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
pubmed: 27733354
pmcid: 5062054
doi: 10.1136/bmj.i4919
Chapter 13: Assessing risk of bias due to missing results in a synthesis. https://training.cochrane.org/handbook/current/chapter-13 . Accessed 15 Sept 2023.
Chapter 13: Assessing risk of bias due to missing results in a synthesis | Cochrane Training. https://training.cochrane.org/handbook/current/chapter-13 . Accessed 4 Nov 2023.
IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25.
pubmed: 24548571
pmcid: 4015721
doi: 10.1186/1471-2288-14-25
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
pubmed: 9310563
pmcid: 2127453
doi: 10.1136/bmj.315.7109.629
Pfeiffer P, Yilmaz M, Möller S, Zitnjak D, Krogh M, Petersen LN, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:412–20.
pubmed: 31999946
doi: 10.1016/S1470-2045(19)30827-7
Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, et al. Bevacizumab in Combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal Cancer: a retrospective study. Oncologist. 2020;25:e469–76.
pubmed: 32162797
doi: 10.1634/theoncologist.2019-0541
Kotani D, Kuboki Y, Horasawa S, Kaneko A, Nakamura Y, Kawazoe A, et al. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. BMC Cancer. 2019;19:1253.
pubmed: 31881856
pmcid: 6935149
doi: 10.1186/s12885-019-6475-6
Nie C, Xu W, Chen B, Lv H, Wang J, Liu Y, et al. An exploration of Trifluridine/Tipiracil Monotherapy and in Combination with Bevacizumab or Immune Checkpoint inhibitors for patients with metastatic colorectal Cancer: a real-world study. Clin Colorectal Cancer. 2023;22:76–84.
pubmed: 36564281
doi: 10.1016/j.clcc.2022.11.005
Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023;388:1657–67.
pubmed: 37133585
doi: 10.1056/NEJMoa2214963
Chida K, Kotani D, Nakamura Y, Kawazoe A, Kuboki Y, Shitara K, et al. Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study. Ther Adv Med Oncol. 2021;13:17588359211009143.
pubmed: 33959196
pmcid: 8064512
doi: 10.1177/17588359211009143
Shibutani M, Nagahara H, Fukuoka T, Iseki Y, Wang EN, Okazaki Y, et al. Combining Bevacizumab with Trifluridine/Thymidine phosphorylase inhibitor improves the survival outcomes regardless of the usage history of Bevacizumab in Front-line treatment of patients with metastatic colorectal Cancer. Anticancer Res. 2020;40:4157–63.
pubmed: 32620665
doi: 10.21873/anticanres.14415
Okunaka M, Kawazoe A, Nakamura H, Kotani D, Mishima S, Kuboki Y, et al. Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience. Gastric Cancer. 2023;26:1030–9.
pubmed: 37665515
doi: 10.1007/s10120-023-01427-9
Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34.
pubmed: 24024839
doi: 10.1056/NEJMoa1305275
Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017;28:1862–8.
pubmed: 28449055
pmcid: 5834073
doi: 10.1093/annonc/mdx119
Tian M, Li H, Dong W, Li Y, Jiang T, Lv Y, et al. Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis. World J Surg Oncol. 2023;21:355.
pubmed: 37978547
pmcid: 10656984
doi: 10.1186/s12957-023-03256-7
Zeng T, Fang X, Lu J, Zhong Y, Lin X, Lin Z, et al. Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2022;37:251–8.
pubmed: 34716473
doi: 10.1007/s00384-021-04028-z
Bakkerus L, Buffart LM, Buffart TE, Meyer YM, Zonderhuis BM, Haasbeek CJA, et al. Health-related quality of life in patients with metastatic colorectal Cancer undergoing systemic therapy with or without maximal tumor debulking. J Natl Compr Canc Netw. 2023;21:1059-e10665.
pubmed: 37856212
doi: 10.6004/jnccn.2023.7050